Pluristem Therapeutics (NASDAQ:PSTI) released its earnings results on Thursday. The biotechnology company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01, Fidelity Earnings reports.
Shares of NASDAQ PSTI traded up $0.01 during trading on Friday, reaching $1.19. The company had a trading volume of 84,903 shares, compared to its average volume of 228,865. Pluristem Therapeutics has a 12-month low of $1.06 and a 12-month high of $1.65. The stock has a market cap of $131.77 million, a P/E ratio of -4.76 and a beta of 0.48.
A number of equities research analysts have recently commented on the company. B. Riley assumed coverage on Pluristem Therapeutics in a research note on Tuesday, July 31st. They issued a “buy” rating and a $4.50 target price on the stock. HC Wainwright reissued a “buy” rating and issued a $3.50 target price on shares of Pluristem Therapeutics in a research note on Friday, September 28th. Finally, Zacks Investment Research raised Pluristem Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, July 12th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $3.13.
COPYRIGHT VIOLATION WARNING: “Pluristem Therapeutics (PSTI) Releases Earnings Results, Beats Expectations By $0.01 EPS” was originally published by Macon Daily and is the property of of Macon Daily. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at https://macondaily.com/2018/11/09/pluristem-therapeutics-psti-releases-earnings-results-beats-expectations-by-0-01-eps.html.
Pluristem Therapeutics Company Profile
Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.
Featured Article: The benefits and drawbacks of dollar cost averaging
Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.